Common Stock, par value $0.001 per share
- Symbol
- NEO
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
NeoGenomics, Inc.
NEONASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 17, 2026, NeoGenomics, Inc. issued a press release reporting its results for its fourth fiscal quarter of 2025 and full year ended December 31, 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.…
Press release in this filing
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results Full year revenue increased 10% to $727 million; →Recent company filings
- 10-Q filingOct 28, 2026
- Results of Operations and Financial ConditionOct 28, 2026
- Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 5, 2026
- 4 filingAug 25, 2026
- S-8 filingAug 25, 2026
Registered securities in this filing
NEOGENOMICS, INC. · 8-K · Filed 2026-02-17
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On February 17, 2026, NeoGenomics, Inc. issued a press release reporting its results for its fourth fiscal quarter of 2025 and full year ended December 31, 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.